Kim Yeawon, Lee Heedoo, Manson Scott R, Lindahl Maria, Evans Bradley, Miner Jeffrey H, Urano Fumihiko, Chen Ying Maggie
Division of Nephrology, Department of Internal Medicine.
Division of Urology, Department of Surgery.
J Am Soc Nephrol. 2016 Oct;27(10):2974-2982. doi: 10.1681/ASN.2014100986. Epub 2016 Mar 3.
Endoplasmic reticulum (ER) stress and disrupted proteostasis contribute to the pathogenesis of a variety of glomerular and tubular diseases. Thus, it is imperative to develop noninvasive biomarkers for detecting ER stress in podocytes or tubular cells in the incipient stage of disease, when a kidney biopsy is not yet clinically indicated. Mesencephalic astrocyte-derived neurotrophic factor (MANF) localizes to the ER lumen and is secreted in response to ER stress in several cell types. Here, using mouse models of human nephrotic syndrome caused by mutant laminin β2 protein-induced podocyte ER stress and AKI triggered by tunicamycin- or ischemia-reperfusion-induced tubular ER stress, we examined MANF as a potential urine biomarker for detecting ER stress in podocytes or renal tubular cells. ER stress upregulated MANF expression in podocytes and tubular cells. Notably, urinary MANF excretion concurrent with podocyte or tubular cell ER stress preceded clinical or histologic manifestations of the corresponding disease. Thus, MANF can potentially serve as a urine diagnostic or prognostic biomarker in ER stress-related kidney diseases to help stratify disease risk, predict disease progression, monitor treatment response, and identify subgroups of patients who can be treated with ER stress modulators in a highly targeted manner.
内质网(ER)应激和蛋白质稳态破坏促成了多种肾小球和肾小管疾病的发病机制。因此,开发非侵入性生物标志物以在疾病初期检测足细胞或肾小管细胞中的ER应激至关重要,此时肾脏活检尚无临床指征。中脑星形胶质细胞衍生的神经营养因子(MANF)定位于内质网腔,并在几种细胞类型中响应ER应激而分泌。在此,我们使用由突变型层粘连蛋白β2蛋白诱导的足细胞ER应激引起的人类肾病综合征小鼠模型以及由衣霉素或缺血再灌注诱导的肾小管ER应激引发的急性肾损伤(AKI)小鼠模型,研究了MANF作为检测足细胞或肾小管细胞中ER应激的潜在尿液生物标志物。ER应激上调了足细胞和肾小管细胞中MANF的表达。值得注意的是,与足细胞或肾小管细胞ER应激同时出现的尿MANF排泄先于相应疾病的临床或组织学表现。因此,MANF有可能作为ER应激相关肾脏疾病的尿液诊断或预后生物标志物,以帮助分层疾病风险、预测疾病进展、监测治疗反应,并识别可高度针对性地接受ER应激调节剂治疗的患者亚组。